Mavyret is intended to treat adults with all types of chronic hepatitis C virus with mild or no cirrhosis who have not previously received treatment for the illness. Patients with moderate to severe kidney disease, individuals on dialysis and genotype 1 patients unsuccessfully treated with a different drug are also eligible for treatment.
Mavyret represents the first drug for all hepatitis C genotypes with an eight-week treatment duration. Previously, the standard treatment length for the disease was at least 12 weeks.
More articles on supply chain:
4 latest FDA approvals
Senate passes FDA user fee reauthorization bill
How retail pharmacies are driving down generic drug prices: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
